The estimated Net Worth of Pat Cotroneo is at least $13.1 million dollars as of 15 June 2021. Mr. Cotroneo owns over 4,053 units of FibroGen Inc stock worth over $110,671 and over the last 10 years he sold FGEN stock worth over $8,640,624. In addition, he makes $4,326,390 as Chief Financial Officer at FibroGen Inc.
Sign up
Mr. Cotroneo FGEN stock SEC Form 4 insiders trading
Pat has made over 63 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 4,053 units of FGEN stock worth $103,838 on 15 June 2021.
The largest trade he's ever made was exercising 95,000 units of FibroGen Inc stock on 8 August 2017 worth over $1,273,950. On average, Pat trades about 7,214 units every 23 days since 2014. As of 15 June 2021 he still owns at least 276,677 units of FibroGen Inc stock.
You can see the complete history of Mr. Cotroneo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Pat Cotroneo biography
Pat Cotroneo serves as Chief Financial Officer of the Company. Mr. Cotroneo joined us in 2000 as Controller, was promoted to Vice President of Finance, and subsequently promoted to Chief Financial Officer in 2008. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. Prior to SyStemix, he was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a Bachelor of Science degree with honors from the University of San Francisco and was selected a Louise M. Davies scholar.
What is the salary of Pat Cotroneo?
As the Chief Financial Officer of FibroGen Inc, the total compensation of Pat Cotroneo at FibroGen Inc is $4,326,390. There are 4 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of $5,856,450.
How old is Pat Cotroneo?
Pat Cotroneo is 56, he's been the Chief Financial Officer of FibroGen Inc since 2008. There are 15 older and 6 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
What's Pat Cotroneo's mailing address?
Pat's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Insiders trading at FibroGen Inc
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff et Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
What does FibroGen Inc do?
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
What does FibroGen Inc's logo look like?
Complete history of Mr. Cotroneo stock trades at FibroGen Inc
FibroGen Inc executives and stock owners
FibroGen Inc executives and other stock owners filed with the SEC include:
-
Kin-Hung Yu,
Chief Medical Officer -
James Schoeneck,
Chairman of the Board -
Elias Kouchakji,
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance -
Christine Chung,
Senior Vice President, China Operations -
Pat Cotroneo,
Chief Financial Officer -
Enrique A. Conterno,
CEO & Director -
Dr. Elias Kouchakji,
Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance -
Pat Cotroneo,
Exec. Advisor to CEO -
Suzanne Blaug,
Independent Director -
Thane Wettig,
Chief Commercial Officer -
Dr. Mark Eisner M.D., M.P.H.,
Chief Medical Officer -
Thomas Kearns,
Lead Independent Director -
Jeffrey Edwards,
Independent Director -
Rory Riggs,
Independent Director -
Gerald Lema,
Independent Director -
Jeffrey Henderson,
Independent Director -
Maykin Ho,
Independent Director -
Kalevi Kurkijarvi,
Independent Director -
Toshinari Tamura,
Independent Director -
James A. Schoeneck,
Chairman -
Benjamin Cravatt,
Director -
Aoife Brennan,
Director -
Thane Wettig,
Chief Commercial Officer -
Percy Carter,
Chief Scientific Officer -
Enrique Conterno,
Chief Executive Officer, Director -
Dr. John J. Hunter Ph.D.,
Chief Scientific Officer -
Dr. Michael J. Martinelli,
Sr. VP of Technical Devel. -
Juan Graham,
Chief Financial Officer -
Dr. Barry A. Berkowitz Ph.D.,
Founder -
Jorma Routti,
Director -
K Peony Yu,
Chief Medical Officer -
Thomas B Neff,
Chief Executive Officer -
Mark Eisner,
EVP, Chief Medical Officer -
Julian N Stern,
Director -
Frank H Md Valone,
Chief Medical Officer -
Miguel Madero,
Director -
Pharma Inc. Astellas,
-
Juan Graham,
CHIEF FINANCIAL OFFICER -
Deyaa Adib,
Chief Medical Officer